|Bid||0.4350 x 0|
|Ask||0.4750 x 0|
|Day's Range||0.4400 - 0.4450|
|52 Week Range||0.2100 - 0.7200|
|Beta (5Y Monthly)||1.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar. 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Aug. 16, 2011|
|1y Target Est||N/A|
VANCOUVER, British Columbia, March 11, 2020 -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and six months ended December 31,.
Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce that it has been named a 2020 Venture 50 Company, ranked among the TSX Venture Exchange’s top 50 best performing companies. The ranking comprises ten companies from each of five key industry sectors.
Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce the completion of a research and development contract sponsored by a top 10 global pharma. The contract deliverables will see Novoheart further expand its current testing capabilities of the MyHeart™ Platform by designing and developing a new versatile High-Throughput microplate which will allow the screening of hundreds of drugs using engineered human ventricular Cardiac Tissue Strips (hvCTS).
Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce that its wholly owned subsidiary Novoheart Limited has been awarded a further grant from the Innovation and Technology Commission (ITC) of Hong Kong SAR Government. Combined with a cash rebate scheme and funding for hiring R&D talent, the Company is expected to receive a total of over HK$10 million ($1.67 million CAD) in grant awards from the ITC over the next 2 years.
Novoheart (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH), a global stem cell biotech company that invented and commercialized the world’s first and only “human heart-in-a-jar” model for drug discovery and development, is pleased to announce an exclusive licensing agreement with Harvard University’s Office of Technology Development. The agreement enables Novoheart to combine its state-of-the-art MyHeartTM Platform with Harvard’s pioneering tissue-engineered scale model of the heart ventricle and bioreactor technology.
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announced that it is changing its fiscal year-end to December 31, from its current fiscal year-end of June 30. The notice for the year-end change required under National Instrument 51-102 – Continuous Disclosure Obligations has been filed under the Company’s profile at www.sedar.com. Novoheart believes this change of year-end will better align the Company’s financial reporting with industry peer groups in the biotech sector, which will allow investors to more easily compare quarterly and annual financial results.
Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announced today that Joseph Leung resigned as Chief Financial Officer and Corporate Secretary of the Company effective immediately.
Heart failure (HF) is a global pandemic with an estimated 64.3 million cases worldwide in 2017, with an increasing trend in prevalence2. The annual global economic burden of HF is estimated at over US$100 billion3.
VANCOUVER, British Columbia, Nov. 19, 2019 -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three months ended September 30, 2019..
FWB: 3NH) announces that it has granted incentive stock options to purchase an aggregate of 1,150,000 common shares of the Company (the “Options”) to non-executive directors of the Company. The Options have an exercise price of $0.30 per common share. The Options expire on October 1, 2024 and vest 40% on the first anniversary of the grant date and 30% on each of the second and third anniversaries of the grant date. The Options granted are subject to the acceptance of the TSX Venture Exchange.
FWB: 3NH), a global stem cell biotechnology company, demonstrate advanced capabilities for drug screening as well as disease modeling which can lead to safer drugs with better efficacy, according to new research. Novoheart’s bio-artificial human heart tissues and chambers are used by global pharmaceutical companies for accurate preclinical testing of the effectiveness and safety of new drugs, with a mission of maximizing the successes in drug discovery while minimizing costs and harm caused to patients.
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...
FWB: 3NH) is pleased to announce that it has completed its previously announced acquisition (the “Acquisition”) of all of the shares of Xellera Therapeutics Limited (“XT”). As consideration for the Acquisition, Novoheart has issued an aggregate of 93,000,000 common shares (“Novoheart Shares”) and pre-paid common share purchase warrants (“Pre-paid Warrants”) at a deemed price of $0.3635 per share, for an aggregate consideration of $33,805,000. “The completion of the acquisition of XT is a significant milestone in achieving our long-term goal of developing clinical grade cell and gene based therapies for heart failure. It reinforces our aspiration to revolutionize human cardiac tissue engineering for the benefits of mankind.” said Allen Ma, Chairman of Novoheart’s Board.
Novoheart Holdings Inc. (“Novoheart” or the “Company”) announced the appointment of Joseph Leung (“Joseph”) as its new Chief Financial Officer (“CFO”) and Corporate Secretary. Joseph will be replacing Dr. Camie Chan, who has been serving as the Company’s interim CFO and Corporate Secretary. Joseph has accumulated nearly two decades of experience in the field of financial management and accounting, specializing in mergers and acquisitions, compliance and risk management, and the development and monitoring of control systems.
VANCOUVER , June 6, 2019 /CNW/ - Trading resumes in: Company: Novoheart Holdings Inc. TSX-Venture Symbol: NVH (All Issues) Resumption (ET): 9:30, 6/7/2019 IIROC can make a decision to impose a temporary ...
FWB: 3NH) announced that effective on May 27, 2019, it has entered into a definitive non-arm’s length agreement to acquire (the “Acquisition”) all of the shares of Xellera Therapeutics Limited (“XT”) for C$33,805,000 to be satisfied through the issuance of 93,000,000 common shares of the Company (“Common Shares”). Since its public listing in 2017, the Company has been focusing on launching its pre-clinical programs. The Acquisition will accelerate progression of the Company’s current business scope to include the development of clinical assets with the availability of unique expertise and professional networks in clinical trials and related regulatory requirements in the US, EU and HK/China, and a state-of-the-art GMP facility currently being established, with a target completion date in the first half of 2020, to be compliant with international standards for manufacturing clinical-grade advanced therapeutic products (ATP) for clinical trials and other applications, thereby leading to new revenue streams.